The present invention relates to a crystal form of a dimaleate of a tyrosine kinase inhibitor and a preparation method therefor. Specifically, the present invention relates to a crystal form IV of a dimaleate of an epidermal growth factor receptor (EGFR) inhibitor and a preparation method therefor. The crystal form IV has good chemical stability and crystal form stability and may be better used in clinical treatment.